Oral amoxicillin for management of fast breathing or chest indrawing pneumonia without danger signs in children aged 2-59 months: a systematic review and meta-analysis.

TL;DR

Systematic review of 7 trials found oral amoxicillin reduces treatment failure vs no antibiotics for fast breathing pneumonia (16% reduction) and is non-inferior to injectable antibiotics for chest indrawing pneumonia without danger signs, with a 72% lower mortality rate with oral amoxicillin.

Key findings

• Oral amoxicillin reduced treatment failure by 16% compared to no antibiotics for fast breathing pneumonia in children 2-59 months (RR 0.84, 95% CI 0.75-0.94)
• Treatment failure rates were similar between oral amoxicillin and injectable antibiotics for chest indrawing pneumonia at day 6 and day 14
• Mortality was 72% lower with oral amoxicillin vs injectable antibiotics for chest indrawing pneumonia (RR 0.28, 95% CI 0.09-0.86)
• Serious adverse events did not differ significantly between oral amoxicillin and comparison groups

Why this matters at the bedside

Supports WHO recommendation of oral amoxicillin as first-line therapy for non-severe pneumonia in young children, particularly relevant for low-resource settings where injectable antibiotics and hospitalization may be limited. Finding of lower mortality with oral amoxicillin versus injectables warrants clinical attention despite small absolute risk differences.